Solid Tumor Targeting with GEN-011: An Autologous Multi- Neoantigens-Specific Peripheral-Blood Derived T Cell Therapy

Time: 4:30 pm
day: Day Two


• Importance of tumor-specific neoantigen selection with ATLASTM bioassay for cancer immunotherapies
• Discuss the plan for a robust, scalable, reproducible and closed “PLANET” manufacturing process
• GEN-011 is an autologous, multi-neoantigen-specific T cell therapy with memory T cells phenotype and harboring self-renewing, stem-like characteristics